Polypeptide drug based on butyric acid coupling and application thereof in treatment of anti-glomerular basilar membrane disease

The polypeptide drug m-P14 is transformed through butyric acid coupling technology, which improves its stability and bioavailability in the body, solves the problems of poor stability and low bioavailability in the body, and significantly reduces the anti-glomerular basement membrane. Kidney damage in disease model provides new therapeutic strategies.

CN119074940AActive Publication Date: 2024-12-06PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE)
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411410444.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-12-06
Estimated Expiration
2044-10-10

AI Technical Summary

Technical Problem

Existing polypeptide drugs have poor stability in the body and are low in bioavailability, so they cannot effectively treat anti-glomerular basement membranous diseases. In particular, the classical polypeptide structure has poor stability to proteases, and most biologically active peptides cannot be taken orally.

Method used

A polypeptide drug based on butyric acid coupling was designed to modify the polypeptide sequence through butyric acid or 2-aminobutyric acid, increase linkers such as 6-aminocaproic acid, and modify the peptide TDIPPCPHGWSSLWKGFSFIMF to improve the drug's pharmacopoeia stability and permeability. Membrane ability to form coupled polypeptides m-P14-2A and m-P14-BA.

Benefits of technology

Significantly alleviates renal damage in anti-glomerular basal membranous disease models, and the therapeutic effect is better than the unmodified peptide m-P14, providing a new therapeutic strategy and laying the foundation for clinical trial transformation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074940A_ABST
    Figure CN119074940A_ABST
Patent Text Reader

Abstract

The invention discloses a butyric acid coupling-based polypeptide drug and application thereof in treatment of anti-glomerular basement membrane disease, the polypeptide drug can significantly alleviate kidney injury in an anti-glomerular basement membrane disease model, and the treatment effect of the polypeptide drug is significantly superior to that of m-P14. The invention provides a brand-new treatment strategy for the technical field of treatment of the anti-glomerular basilar membrane disease, lays a foundation for finally realizing transformation of the therapeutic polypeptide to a clinical test, and has a wide clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular, relates to a butyrate-coupled polypeptide drug and its application in the treatment of glomerular basement membrane disease. Background Art

[0002] Glomerulonephritis is one of the important causes of chronic kidney disease in my country, among which the immune inflammatory mechanism is the core pathogenesis. Developing immunological treatment for the disease based on the cause can delay the progression of the disease, and it is also a specific treatment method that needs to be developed in the clinic. Among glomerulonephritis, anti-glomerular basement membrane (GBM) disease is a classic model of important immune renal visceral disease and also the glomerulonephritis with the worst prognosis. Anti-GBM disease is a severe autoimmune kidney disease. The key link in its pathogenesis is the exposure of the glomerular basement membrane (GBM) autoantigen α3(IV)NC1 and the production of anti-GBM autoantibodies. After the antigen-antibody combination, it mediates the immune inflammatory response, leading to severe kidney damage.

[0003] The inventor's research team of this application has spent more than 10 years to improve the immune pathogenesis of the disease, clarify the pathogenic T cell antigen epitope α3-P14 and its key amino acids, and use this epitope to establish an anti-GBM disease rat model, laying the foundation for the development of immunotherapy. Using the unique structure of the α1-5 chain of type IV collagen in the human basement membrane, the inventor's research team used non-pathogenic α1-P14 as a template to replace the key amino acids WIxLWxGFxF of α3-P14 and designed a modified peptide m-P14. Treatment was carried out in an animal model of anti-GBM nephritis, and it was found that the glomerular crescents in rats were significantly reduced or completely disappeared. The therapeutic peptide exerts a therapeutic effect by intervening in antigen presentation and regulating T cell differentiation.

[0004] However, the classic peptide structure has poor stability to proteases in the body and will be quickly degraded after entering the body. In addition, most bioactive peptides have poor bioavailability and cannot be taken orally. They need to be developed by changing the dosage form to obtain a suitable route of administration. Based on the above factors, it is necessary to structurally modify and chemically transform the active peptides. The purposes of active peptide modification are varied, mainly including improving the affinity and selectivity of active peptides to receptors; enhancing the pharmacokinetic stability of polypeptide molecules, reducing the degradation of active peptides in the body or reducing the elimination of active peptides in the body; improving the membrane permeability of active peptides; improving the water solubility of hydrophobic peptides, etc. Designing and synthesizing an effective, structurally optimized coupled polypeptide drug is of great significance to the ultimate transformation of therapeutic polypeptides into clinical trials. Summary of the invention

[0005] In view of this, the purpose of the present invention is to provide a butyrate-coupled polypeptide drug and its application in the treatment of glomerular basement membrane disease in the art to solve the above-mentioned technical problems existing in the prior art.

[0006] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0007] The first aspect of the present invention provides a coupled polypeptide based on butyrate coupling.

[0008] Furthermore, the coupled polypeptide is obtained by modifying the polypeptide sequence with butyric acid or 2-aminobutyric acid;

[0009] The coupled polypeptide obtained by modifying the polypeptide sequence with butyric acid is: C4H8O2-(K)n-linker-TDIPPCPHGWSSLWKGFSFIMF;

[0010] The coupled polypeptide obtained by modifying the polypeptide sequence with 2-aminobutyric acid is: C4H9NO2-(K)n-linker-TDIPPCPHGWSSLWKGFSFIMF.

[0011] Furthermore, the linker comprises 6-aminohexanoic acid and / or β-alanine.

[0012] Furthermore, the linker is 6-aminohexanoic acid.

[0013] Furthermore, n is selected from any integer value between 3-8.

[0014] Furthermore, n=5.

[0015] In some embodiments, the butyric acid (BA) is a straight-chain saturated fatty acid with a molecular weight of 88.11, a chemical formula of C4H8O2, and a melting point of -7.9°C. Butyric acid is a rancid, sour, oily liquid at room temperature and pressure, and is miscible with water, ethanol, and ether. In a specific embodiment of the present invention, the butyric acid is also referred to as BA.

[0016] In some embodiments, the 2-aminobutyric acid (2-Aminoisobutyric acid, 2A) is a chemical substance with a molecular weight of 103.1198. Colorless monoclinic crystals. Melting point 335°C, sublimation starts at 280°C. Easily soluble in water, poorly soluble in alcohol, insoluble in ether. Its corresponding chemical formula is C4H9NO2. In a specific embodiment of the present invention, the 2-aminobutyric acid is also called 2A.

[0017] In some embodiments, the 6-aminohexanoic acid (6-Aminohexanoic acd, Ahx) is a linear amino acid analog containing six carbon atoms, with an amino group and a carboxyl group. It is often used as a linker in peptide synthesis to connect different molecular fragments. In a specific embodiment of the present invention, the 6-aminohexanoic acid is also called Ahx.

[0018] In some embodiments, coupled polypeptides having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% sequence homology with the sequence of the coupled polypeptides as described above of the present invention also fall within the scope of protection of the present invention.

[0019] In addition, the present invention also provides coupled polypeptide derivatives corresponding to the coupled polypeptide as described above, wherein the coupled polypeptide derivatives include coupled polypeptide derivatives obtained by modifying the coupled polypeptide as described above, or coupled polypeptide derivatives obtained by connecting a conjugate to the coupled polypeptide as described above.

[0020] Furthermore, the modification includes hydrophobic group modification, esterification modification, amidation modification, glycosylation modification, acetylation modification, pegylation modification, alkylation modification, amino modification, carbonylation modification, phosphorylation modification, methylation modification, hydroxylation modification, carboxylation modification, sulfation modification and / or cyclization modification.

[0021] Furthermore, the conjugate includes a fluorescent dye, a metal ion, a radioactive compound, an enzyme and / or a cell penetrating peptide.

[0022] In some embodiments, the coupled polypeptide derivative of the present invention may be a polypeptide derivative obtained by modifying the N-terminus of the coupled polypeptide of the first aspect of the present invention with a hydrophobic group. Exemplarily, the hydrophobic group includes, but is not limited to, any one or more combinations of palmitic acid, stearic acid, oleic acid, myristic acid, linoleic acid, cholesterol and arachidonic acid.

[0023] In some embodiments, the coupled polypeptide derivatives of the present invention may be polypeptide derivatives obtained by connecting a cell penetrating peptide to the N-terminus of the coupled polypeptide described in the first aspect of the present invention. Cell penetrating peptides are also known as targeting polypeptides, protein transduction domains, Trojan horse peptides, etc., which are a large class of short amino acid sequences (5-30 residues) that can pass through biological membranes and deliver a variety of compounds into cells, including small molecules, proteins, viruses, nucleic acids, imaging agents, and drugs. The cell penetrating peptides of the present invention include any cell penetrating peptides known in the art.

[0024] In some embodiments, the conjugate can be a detection agent, which can be any substance with detectable physical or chemical properties. Exemplarily, detection agents include but are not limited to fluorescent dyes (e.g., fluorescein isothiocyanate, Texas Red, rhodamine, etc.), radioactive labels (e.g., 125 I. 35 S. 14 C. 3 H or 32 P, etc.), in particular, radiolabeled (e.g., 55 Mn, 162 Dy, 157 Gd, 52 Cr or 56 Fe, etc.), metal ions (e.g. 111 In, 68 Ga, 72 As, 97 Such as 67 Ga, 89 Zr or 201 Tl, etc.), enzymes (e.g., horseradish peroxidase, alkaline phosphatase, and other enzymes commonly used in ELISA), electron transfer agents (e.g., metal binding proteins, etc.), luminescent and chemiluminescent labels (e.g., fluorescein, 2,3-dihydrophthalazine or luminol, etc.), magnetic beads, and colorimetric labels, such as colloidal gold or colored glass or plastic beads (e.g., polystyrene or polypropylene, etc.).

[0025] In addition, the present invention also provides a pharmaceutically acceptable salt corresponding to the coupled polypeptide as described above, and the pharmaceutically acceptable salt corresponding to the coupled polypeptide refers to an acid salt formed by the coupled polypeptide and an inorganic and / or organic acid and a basic salt formed with an inorganic and / or organic base. Preferably, it is a pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salt, but other salts are also useful. The pharmaceutically acceptable salt of the coupled polypeptide can be formed, for example, by the following method: reacting the coupled polypeptide with a certain amount of acid or base in a medium, such as a medium in which the salt is precipitated or an aqueous medium (lyophilized after the reaction).

[0026] Specific pharmaceutically acceptable salts include those salts that are suitable for contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic reaction, etc., and are commensurate with a reasonable benefit or risk ratio within the scope of sound medical judgment. Pharmaceutically acceptable salts (pharmaceutically acceptable salts) are well known in the art. Pharmaceutically acceptable salts of the coupled polypeptides of the present invention include salts derived from suitable inorganic and organic acids and inorganic and organic bases.

[0027] In some embodiments, suitable acids for preparing pharmaceutically acceptable salts of the coupled polypeptide include, but are not limited to, maleic acid, acylated amino acids, acetic acid, 2,2-dichloroacetic acid, lauric acid, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, benzoic acid, 4-acetamidobenzoic acid, boric acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, malonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, 1,5-naphthalenedisulfonic acid, hexanoic acid, cinnamic acid, citric acid, cyclamic acid, cyclohexylaminosulfonic acid, dodecylsulfuric acid , 1-hydroxy-2-naphthoic acid, oxalic acid, palmitic acid, decanoic acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, L-glutamic acid, α-ketoglutaric acid, glycolic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, horse urea, hydrobromic acid, hydrochloric acid, sebacic acid, stearic acid, succinic acid, hydroiodic acid, (+)-L-lactic acid, (-)-L-malic acid, phosphoric acid, L-pyroglutamic acid, tannic acid, L-tartaric acid, glucaric acid, salicylic acid, 4-aminosalicylic acid, sulfuric acid, thiocyanic acid, p-toluenesulfonic acid, undecylenic acid and / or valeric acid.

[0028] In some embodiments, suitable bases for preparing pharmaceutically acceptable salts of the coupled polypeptide include, but are not limited to, inorganic bases such as magnesium hydroxide, calcium hydroxide, potassium hydroxide, zinc hydroxide and / or sodium hydroxide; organic bases such as primary, secondary, tertiary, butyl, aliphatic and aromatic amines including L-arginine, choline, dimethylamineethanol, diethanolamine, phenethylbenzylamine, dimethylamine, propylamine, dibenzylethylenediamine, diethylamine, ethanolamine, ethylamine, ethylenediamine, diisopropylamine, diethylaminoethanol, isopropylamine, meglumine, hydrabamine, 1H-imidazole, L-lysine, pyridine, quinuclidine, quinoline, isoquinoline, secondary amines, morpholin, 4-(2-hydroxyethyl)morpholine, methylamine, piperidine, piperazine, propylamine, pyrrolidine, 1-(2-hydroxyethyl)pyrrolidine, triethanolamine, triethylamine, N-methyl-D-glucamine, trimethylamine, trishydroxymethylaminomethane and / or tromethamine.

[0029] A second aspect of the present invention provides a pharmaceutical composition.

[0030] Furthermore, the pharmaceutical composition comprises the coupled polypeptide described in the first aspect of the present invention.

[0031] In some embodiments, the pharmaceutical composition comprises a therapeutically and / or prophylactically effective amount of the coupled polypeptide according to the first aspect of the present invention.

[0032] In some embodiments, the pharmaceutical composition may further comprise a second therapeutic agent.

[0033] In some embodiments, the second therapeutic agent is another drug that can be used to treat and / or prevent GBM disease.

[0034] In some embodiments, the other drugs that can be used to treat and / or prevent anti-glomerular basement membrane disease include but are not limited to: hydrocortisone acetate, prednisone acetate, dexamethasone, betamethasone, cyclophosphamide, tacrolimus, cyclosporine, mycophenolate mofetil, methylprednisolone, dermatan sulfate, glucosamine sulfate, glycosaminoglycans, nifedipine, and amlodipine.

[0035] In the present invention, the second therapeutic agent is not particularly limited, and any drug that can be used to treat and / or prevent anti-glomerular basement membrane disease, or to assist in the treatment and / or prevention of anti-glomerular basement membrane disease, belongs to the category of the second therapeutic agent. In the case where the present invention has clearly proved through experiments that the coupled polypeptide has the effect of treating and / or preventing anti-glomerular basement membrane disease, those skilled in the art can combine the coupled polypeptide with other drugs for the treatment and / or prevention of anti-glomerular basement membrane disease according to actual needs. Therefore, the use of the coupled polypeptide described in the first aspect of the present invention as the only active ingredient or the use of the coupled polypeptide described in the first aspect of the present invention and any one or more of the above-mentioned second therapeutic agents as active ingredients for the treatment and / or prevention of anti-glomerular basement membrane disease falls within the protection scope of the present invention.

[0036] A third aspect of the present invention provides a pharmaceutical preparation.

[0037] Furthermore, the pharmaceutical preparation comprises the coupled polypeptide described in the first aspect of the present invention.

[0038] Further, the pharmaceutical preparation comprises a pharmaceutically acceptable carrier and / or excipient;

[0039] Optionally, the dosage form of the pharmaceutical preparation includes injection, lyophilized powder injection, microspheres, powder, powder spray, capsule, tablet, pill, nasal spray, aerosol, enteric coating, microemulsion or composite emulsion.

[0040] In some embodiments, the pharmaceutical preparation can be prepared according to any preparation method known in the art. For this purpose, if necessary, the coupled polypeptide can be combined with one or more solid or liquid excipients to prepare a suitable administration form or dosage form for human use.

[0041] In some embodiments, the dosage form of the pharmaceutical preparation includes a dosage form for enteral administration or a dosage form for parenteral administration.

[0042] In some embodiments, the enteral dosage form includes solutions, granules, tablets, capsules, suspensions, powders, sustained release agents, effervescent agents, emulsions, syrups, drops, and / or chewable agents.

[0043] In some embodiments, the non-parenteral dosage form includes an injection dosage form, a respiratory tract dosage form, a cavity dosage form, a mucosal dosage form and / or a skin dosage form.

[0044] In the present invention, the dosage form of the pharmaceutical preparation is not particularly limited. In some embodiments, the pharmaceutical composition of the present invention as described above can be prepared into a pharmaceutical preparation of injection or oral preparation, including but not limited to: oral liquid preparation, granules, injection, tablets, capsules, pills, powders, sustained-release preparations, suppositories, aerosols, nano preparations, tinctures, syrups, wine preparations, and dew preparations. Those skilled in the art can select a suitable dosage form known in the art according to actual needs (e.g., improving the bioavailability of the drug, improving the patient's medication compliance, etc.).

[0045] In some embodiments, the coupled polypeptides provided by the present invention, the pharmaceutical compositions comprising the coupled polypeptides, or the pharmaceutical preparations comprising the coupled polypeptides can be administered in the form of unit doses, and the administration routes include, but are not limited to, enteral or parenteral, such as oral, intramuscular, subcutaneous, nasal, oral mucosa, skin, peritoneum or rectum, etc. The dosage forms include, but are not limited to, tablets, pills, powders, granules, solutions, capsules, dripping pills, aerosols, suspensions, emulsions, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections, etc. It can be a common preparation, a sustained-release preparation, a controlled-release preparation, and various microparticle delivery systems.

[0046] In some embodiments, in order to prepare the unit dosage form containing the coupled polypeptide into tablets, various excipients known in the art can be widely used. Examples of excipients include, but are not limited to: diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, calcium carbonate, microcrystalline cellulose, etc.; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethyl cellulose, polyvinyl pyrrolidone, etc.; disintegrants, such as dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, sodium dodecyl sulfate, etc.; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, etc.; absorption promoters, such as quaternary ammonium salts, sodium dodecyl sulfate, etc.; lubricants, such as talc, silicon dioxide, corn starch, stearate, etc. The tablets can be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets.

[0047] In some embodiments, in order to prepare the unit dosage form containing the coupled polypeptide into a pill, various excipients known in the art can be widely used. Examples of excipients include, but are not limited to: diluents and absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc.; binders such as gum arabic, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrants, such as agar powder, dry starch, alginate, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc.

[0048] In some embodiments, in order to prepare a unit dosage form containing a coupled polypeptide into a capsule, the active ingredient (coupled polypeptide) is mixed with the above-mentioned various excipients, and the resulting mixture is placed in a hard gelatin capsule or a soft capsule. The active ingredient (coupled polypeptide) can also be made into a microcapsule, suspended in an aqueous medium to form a suspension, or loaded into a hard capsule or prepared as an injection for use.

[0049] In some embodiments, in order to prepare a unit dosage form containing a coupled polypeptide into an injectable preparation, such as a solution, emulsion, lyophilized powder injection and suspension, all diluents commonly used in the art can be used, including but not limited to: water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, etc. In addition, in order to prepare an isotonic injection, an appropriate amount of sodium chloride, glucose or glycerol can be added to the injectable preparation. In addition, conventional cosolvents, buffers, pH regulators, etc. can also be added.

[0050] In certain embodiments, colorants, preservatives, perfumes, flavorants, sweeteners or other materials may be added to the pharmaceutical preparations as necessary.

[0051] In the present invention, the effective therapeutic and / or preventive dose of the drug, pharmaceutical composition or pharmaceutical preparation can be prescribed in a variety of ways according to the actual formulation method, administration method, patient's age, weight, sex, morbidity, diet, administration time, administration route, excretion rate and reaction sensitivity, and skilled doctors can usually easily determine the prescription and the effective dosage of the prescription for the desired treatment and / or prevention. As long as it can produce the expected therapeutic and / or preventive effect on the disease or related symptoms, such dosage falls within the scope of protection of the present invention.

[0052] The fourth aspect of the present invention provides a method for preparing the coupled polypeptide according to the first aspect of the present invention.

[0053] Furthermore, the method comprises using butyric acid or 2-aminobutyric acid to modify the polypeptide sequence TDIPPCPHGWSSLWKGFSFIMF to prepare the coupled polypeptide described in the first aspect of the present invention.

[0054] In addition, the present invention also provides a method for treating and / or preventing anti-glomerular basement membrane disease, the method comprising the following steps: administering a therapeutically and / or preventively effective amount of the coupled polypeptide described in the first aspect of the present invention, the pharmaceutical composition described in the second aspect of the present invention and / or the pharmaceutical preparation described in the third aspect of the present invention to a subject in need.

[0055] In some embodiments, the subject includes mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class Mammalia: humans, non-human primates such as chimpanzees and other apes and monkeys; farm animals such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs and cats; laboratory animals, including rodents such as rats, mice and guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, etc. In one embodiment of the present invention, the subject is a human. The term subject includes confirmed patients.

[0056] In some embodiments, the route of administration includes, but is not limited to, oral, topical, intravenous, intramuscular, subcutaneous, intraperitoneal, intradermal, intranasal, intrapulmonary, intrarectal, etc. In a specific embodiment, the dosage that is beneficial to the subject can be determined by a clinician based on factors such as the type, age, weight, general disease condition, and administration method of the subject for administration.

[0057] In some embodiments, the effective amount refers to the amount of the drug, pharmaceutical composition or pharmaceutical preparation that effectively produces the desired prevention, relief or treatment effect. Depending on the active ingredient (in the present invention, especially the coupled polypeptide or its pharmaceutically acceptable salt, pharmaceutical composition or pharmaceutical preparation as described above), symptoms and their severity, the age of the treated mammal and other factors, the amount of the drug, pharmaceutical composition or pharmaceutical preparation of the present invention that reaches the effective amount will also vary accordingly, but the specific dosage can be routinely determined by a person of ordinary skill in the art based on the knowledge in the art mastered by him / her combined with the content disclosed in the present invention, and the dosage that can produce the above-mentioned effect is within the scope of protection of the present invention.

[0058] A fifth aspect of the present invention provides any of the following applications:

[0059] (1) Use of the coupled polypeptide according to the first aspect of the present invention in the preparation of a drug for treating and / or preventing glomerular basement membrane disease;

[0060] (2) Use of the coupled polypeptide according to the first aspect of the present invention in the preparation of a pharmaceutical composition for treating and / or preventing glomerular basement membrane disease;

[0061] (3) Use of the coupled polypeptide described in the first aspect of the present invention in the preparation of a pharmaceutical preparation for treating and / or preventing glomerular basement membrane disease.

[0062] In the present invention, the treatment and / or prevention refers to delaying the development of a disease, preventing the development of a disease, and / or reducing the severity of the symptoms that will develop or are expected to develop. Therefore, these terms include improving existing disease symptoms, preventing additional symptoms, improving or preventing potential metabolic causes of symptoms, inhibiting a disorder or disease, for example, preventing the development of a disorder or disease, alleviating a disorder or disease, regressing a disorder or disease, alleviating a condition caused by a disease or disorder, or stopping the symptoms of a disease or disorder. In a specific embodiment of the present invention, the disease is anti-glomerular basement membrane disease.

[0063] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0064] The present invention discloses for the first time a butyrate-coupled polypeptide drug (m-P14-2A (2-aminobutyric acid), m-P14-BA (butyric acid)) for treating anti-glomerular basement membrane disease, and proves through comparative experiments that not all short-chain fatty acids and small molecule polypeptide m-P14 have therapeutic effects on treating anti-glomerular basement membrane disease after coupling, and the butyrate-coupled polypeptide drugs (m-P14-2A, m-P14-BA) provided by the present invention can significantly reduce kidney damage in the anti-glomerular basement membrane disease model, and their therapeutic effects are significantly better than m-P14, that is, the butyrate-coupled polypeptide drugs (m-P14-2A, m-P14-BA) provided by the present invention have achieved unexpected technical effects in treating anti-glomerular basement membrane disease, provide a new treatment strategy for the technical field of anti-glomerular basement membrane disease treatment, and lay the foundation for the ultimate transformation of therapeutic polypeptides into clinical trials, and have broad prospects for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 :Flowchart of m-P14-BA treatment of experimental anti-GBM disease rat model;

[0066] Figure 2:Clinical and immunological indicators of anti-GBM rats treated with m-P14-BA, including: Figure A: From the day of modeling, rats in each group were treated with m-P14-BA, and the urine protein levels of rats in each group gradually increased. The increase in urine protein in the m-P14-BA early and late treatment groups was significantly reduced; Figure B: The urine protein levels in the m-P14-BA early and late treatment groups were significantly lower than those in the disease control group at week 6; Figure C: The blood urea nitrogen levels in the m-P14-BA early and late treatment groups were significantly lower than those in the disease control group at week 6; Figure D: The anti-α3 127-148 antibody production was significantly reduced; Figure E: The production of anti-α3(IV)NC1 integrin antibodies in rats in the m-P14-BA early treatment group at week 6 was significantly reduced, where ****: P < 0.0001, ***: P < 0.001, **: P < 0.01, *: P < 0.05, ns: no statistical difference;

[0067] Figure 3 : Effects of m-P14-BA treatment on anti-GBM glomerulonephritis in WKY rats (pathological characteristics), among which, Figure A-D: Representative immunofluorescence images of glomerular IgG deposition in rats of each group; Figure E-H: Representative images of glomerular crescent formation in rats of each group; Figure I: Statistical graph of the proportion of crescent formation in the kidneys of rats of each group; Figure J: Statistical graph of immunofluorescence intensity of glomerular IgG deposition in the kidneys of rats of each group, among which, ****: P < 0.0001, ***: P < 0.001, **: P < 0.01;

[0068] Figure 4 : The therapeutic effects of stearic acid, albumin, and disulfide bond-coupled peptides. Among them, the urine protein of rats treated with albumin, interchain disulfide bonds, stearic acid-coupled peptides, and m-P14 peptide antibodies 24 hours later (left) had no statistical difference compared with the disease control group; truncated peptides and intrachain disulfide bond-modified peptides (right) also had no statistical difference compared with the disease control group;

[0069] Figure 5 : The therapeutic effect of fatty acid-coupled m-P14 peptide, butyrate-coupled peptide m-P14-BA and m-P14-2A, rat urine protein (left), serum creatinine (middle) and urea nitrogen (right) were significantly reduced after treatment;

[0070] Figure 6 :The 24-hour urine protein in rats treated with butyrate-coupled peptide (m-P14-BA) late treatment (LT) was significantly lower than that in the disease control group, indicating that late treatment is effective;

[0071] Figure 7:Butyrate-modified peptides (m-P14-BA and m-P14-2A) can significantly reduce the level of autoantibodies in peripheral circulation (left), and the CD4+T cells (middle) and B cells (right) in the spleen are also reduced. DETAILED DESCRIPTION

[0072] The present invention is further described below in conjunction with specific examples, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents. The experimental methods used in the following examples are conventional methods unless otherwise specified; the reagents, materials, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0073] Example: Peptide drug obtained by short-chain fatty acid coupled polypeptide (m-P14) and its application in treating anti-glomerular basement membrane disease

[0074] 1. Determine the skeleton modification scheme of small molecule peptide drug m-P14

[0075] The m-P14 (TDIPPCPHGWSSLWKGFSFIMF) small molecule peptide is a hydrophobic peptide and is metabolized quickly in vivo. The inventors of the present application have determined the modification scheme of the m-P14 backbone peptide segment (including: m-P14 (short), m-P14 (interchain SS), m-P14 (intrachain SS), m-P14-2A, m-P14-BA, m-P14-stearic acid, m-P14-albumin) through extensive and in-depth research. Among them, the design of coupling short-chain fatty acids is an innovative design. The peptide drugs obtained by coupling peptides based on 2-aminobutyric acid (2A) and butyric acid (BA) were named m-P14-2A and m-P14-BA, respectively. The peptide drugs obtained by coupling peptides based on interchain SS and intrachain SS disulfide bonds were named m-P14 (interchain SS) and m-P14 (intrachain SS), respectively. The peptide drugs obtained by coupling peptides based on stearic acid and albumin were named m-P14-stearic acid and m-P14-albumin, respectively. The names and sequences of the peptide backbone modified peptides designed and synthesized are detailed in Table 1 below.

[0076] Table 1 Names and sequences of peptides modified by polypeptide backbone

[0077]

[0078] The peptides used in the experiment were synthesized by Beijing Zhongke Yaguang Biotechnology Co., Ltd. using the F-moc method on an automatic peptide synthesizer. The peptides were purified by high-performance liquid chromatography and then detected by mass spectrometry to screen peptides with a final purity of ≥98%. They were stored at -80°C and used to construct experimental animal models.

[0079] Peptide α3127-148 sequence: TDIPPCPHGWISLWGFSFIMF (SEQ ID NO: 3);

[0080] m-P14-BA sequence: Butyric acid-KKKKK-Ahx-TDIPPCPHGWSSLWKGFSFIMF.

[0081] 2. Experimental Materials and Methods

[0082] The present invention uses the pathogenic T cell epitope α3127-148 (α-P14) of anti-GBM nephritis to actively immunize WistarKyoto (WKY) rats to construct an anti-glomerular basement membrane (GBM) nephritis animal model. The experimental groups are divided into an early treatment group (administered from day 0) and a treatment group (administered after the appearance of hematuria or proteinuria). m-P14-BA is injected into α-P14 immune modeling rats as a therapeutic drug, and a negative control group (normal saline) is set up and administered in the same way. The renal function of rats is evaluated by detecting the levels of rat urine protein and blood urea nitrogen; the circulating antibody level and antigen epitope expansion of rats are detected by detecting anti-α3127-148 peptide antibodies or anti-α3 (IV) NC protein antibodies; the degree of renal pathological damage in rats is evaluated by renal tissue immunofluorescence and PAS staining. The specific experimental materials and experimental methods are as follows:

[0083] 2.1 Experimental animals

[0084] The experimental animals used in this study were 5-6 weeks old, 60-80 g female Wistar Kyoto (WKY) rats, specific pathogen free (SPF) grade. This study has been approved by the Experimental Animal Ethics Committee to order animals, ethics number: J2023109. The rats used in the experiment were purchased from Beijing Weitong Lihua Company and kept in the barrier environment (SPF grade) of the Experimental Animal Center of Peking University First Hospital.

[0085] 2.2 Antigen preparation

[0086] Take out the α3127-148 peptide from the -80℃ refrigerator, centrifuge the peptide powder at 3000rpm for 5 minutes, let the powder settle to the bottom of the tube, add 10μL DMSO to dissolve it, and then add an appropriate amount of sterile PBS to mix well to completely dissolve the peptide. Add an equal volume of complete Freund's adjuvant to a 5mL centrifuge tube, mix it evenly with the peptide PBS solution at a ratio of 1:1, and vortex for more than 40 minutes to fully emulsify.

[0087] 2.3 Animal immunization and treatment grouping

[0088] The α3127-148 peptide solution emulsified with complete Freund's adjuvant was injected subcutaneously in the bilateral hind foot pads at a dose of 400 μg / kg to construct an experimental anti-GBM disease model. The rats were randomly divided into 4 groups, with 6 rats in each group. The disease control group was not treated from the day of immune modeling; the early treatment group began intraperitoneal injection of m-P14-BA treatment until the day of sacrifice; the late treatment group began intraperitoneal injection of m-P14-BA treatment after the onset of GBM disease symptoms (after hematuria or proteinuria was detected); the control group was given an equal amount of normal saline intraperitoneal injection as a control, which lasted until the 42nd day after modeling. For the specific experimental process, see Figure 1 .

[0089] 2.4 Mouse specimen collection

[0090] Plasma specimens: After anesthetizing rats, the rat medial canthus venous blood was collected with a capillary tube and placed in an EDTA anticoagulant tube. The blood was centrifuged at 3000 rpm for 15 minutes at 4°C, and the upper plasma was collected and stored at -40°C.

[0091] Urine specimens: Rats were placed in rat metabolic cages at a fixed time each week, provided with adequate water and feed, and urine was collected for 24 hours, and the total amount of urine for 24 hours was recorded. Centrifuge at 3000 rpm for 30 minutes at 4°C, and 1 mL of supernatant was aspirated and stored at -40°C.

[0092] Kidney specimens: 6 weeks after immunization, the rats were anesthetized and sampled, and 5% sodium pentobarbital was injected intraperitoneally at a dose of 0.1 mL / 100 g. After disinfection, the rat's abdominal cavity was surgically cut open, the left kidney was removed, and it was repeatedly rinsed in physiological saline. Two pieces of cortex were cut, one was fixed in 4% paraformaldehyde solution for making paraffin sections, and the other was placed in a cryopreservation tube and frozen in liquid nitrogen for preparing frozen sections.

[0093] 2.5 Biochemical tests of rat blood and urine

[0094] After the blood and urine samples of the rats were collected, the urine protein was detected by the biuret method, and the blood urea nitrogen concentration was detected by urease. This part was commissioned to technicians to use an automatic biochemical analyzer for testing.

[0095] 2.6 IgG immunofluorescence staining of kidney tissue

[0096] 1) The frozen renal cortex was embedded in OCT embedding medium and 8 μm thick frozen sections were prepared.

[0097] 2) Precool acetone at -20℃, and fix the slices with acetone at -20℃ for 10 minutes.

[0098] 3) Wash with PBS three times and circle the tissue with a tissue pen.

[0099] 4) Blocking: Add 3% BSA blocking solution dropwise to the tissue and block at 37°C for 1 hour.

[0100] 5) Incubation with primary antibody: dilute goat anti-rat IgG (Jackson, USA, FITC-labeled) with PBS at 1:50, cover the tissue with antibody dilution solution, and incubate at 37°C for 1 hour.

[0101] 6) Wash 3 times with PBS.

[0102] 7) Sealing: Add 1 drop of DAPI-containing mounting medium and seal the slide from one corner with a coverslip.

[0103] 8) Store at 4°C away from light and photograph using a fluorescence microscope in a dark room within one week.

[0104] 2.7 Periodic acid-Schiff stain (PAS) staining of rat kidney pathology

[0105] 1) The renal cortex was fully fixed with 4% formalin fixative, and the tissue was dehydrated with different concentrations of alcohol, and immersed in a xylene solution to make it transparent. The transparent tissue was embedded in melted paraffin, and after the paraffin solidified, 3 μm slices were cut on a microtome, the slices were ironed flat, and dried in a constant temperature box to make paraffin tissue sections. This part of the operation was entrusted to Qu Lei, a technician in the pathology room of the Department of Nephrology of Peking University Hospital.

[0106] 2) Before staining paraffin sections, use xylene to remove the paraffin in the sections. Soak and dewax in two tanks, each for 15 minutes, and then put them into new xylene to fully dewax them.

[0107] 3) Hydrate the slices in graded alcohols, using 100% alcohol, 75% alcohol, and 50% alcohol. Finally, wash the slices in PBS for 3 times.

[0108] 4) Add periodic acid solution and incubate at room temperature in the dark for 20 minutes, then wash three times with PBS.

[0109] 5) Add Schiff's reagent dropwise, incubate at room temperature for 30 minutes, soak in 40-60℃ water for 40 minutes, and rinse with tap water for 10 minutes after natural cooling.

[0110] 6) Hematoxylin staining: Add hematoxylin staining solution to the tissue and let it stand for 8 minutes at room temperature to stain. Rinse with running water for 5 minutes to turn blue.

[0111] 7) After staining, the sections were dehydrated and made transparent with gradient alcohol and xylene, 1 drop of neutral gum was added to the sections, and a cover slip was carefully placed on one corner to seal the sections.

[0112] 8) After the slices were placed in a fume hood to dry naturally, they were photographed under an optical microscope under bright field.

[0113] 2.8 Detection of circulating antibodies in rats by enzyme linked immunosorbent assay (ELISA)

[0114] 1) Antigen: Dissolve the α3127-148 peptide or α3(IV)NC protein in DMSO, and then dilute the peptide to 2 mg / mL with 0.05 mmol / L carbonate buffer.

[0115] 2) Coating: Add 100 μL of 2 μg / mL α3127-148 peptide solution to each well of a 96-well ELISA plate for coating. Use 0.05 mmol / L carbonate buffer as non-antigen coating wells, 100 μL per well, and place the ELISA plate at 4°C overnight.

[0116] 3) Take out the ELISA plate, pour out the liquid in the plate, add 300 μL 0.1% PBST solution to each well, wash 5 times, and pat dry on absorbent paper.

[0117] 4) Take out the rat plasma to be tested from the -40℃ refrigerator, wait for the plasma to melt and vortex to mix, dilute the plasma sample with 1% BSA-0.1% PBST at a ratio of 1:100, add 100 μL to each well, set up a positive control well and a blank control well on each plate, and incubate at 37℃ for 30 minutes.

[0118] 5) Wash the plate 5 times with PBST.

[0119] 6) Dilute alkaline phosphatase-labeled goat anti-rat IgG at a dilution ratio of 1:5000 with 0.1% PBST, add 100 μL to each well, and incubate at 37° C. for 30 minutes.

[0120] 7) Wash the plate 5 times with PBST.

[0121] 8) Prepare alkaline phosphatase colorimetric solution, add 100 μL to each well, and develop color at room temperature.

[0122] 9) Use an ELISA reader to read the OD value at a wavelength of 405 nm, read the value every 5 minutes, and record the OD value.

[0123] 3. Experimental results

[0124] 3.1m-P14-BA treatment can effectively reduce renal injury in the rat anti-GBM nephropathy model

[0125] Rats developed proteinuria in the 3rd to 4th week after α3127-148 peptide modeling, and as the course of the disease prolonged, the urine protein level gradually increased. Figure 2 A, and the urine protein level of m-P14-BA early treatment group and late treatment group decreased. Among them, the early treatment group was the most significant: at the 6th week, m-P14-BA early treatment group vs. disease control group: 70.14±65.50 vs. 202.6±48.22 mg / 24h, P=0.0026; the 24-hour urine protein level of the late treatment group was also significantly lower than that of the disease group: late treatment group vs. disease control group: 105.9±50.72 vs. 202.6±48.22 mg / 24h, P=0.007, see Figure 2 B.

[0126] At the 6th week, the blood urea nitrogen (BUN) levels of the rats in the disease control group after modeling were significantly increased compared with those in the healthy control group. After treatment, the blood urea nitrogen levels of the m-P14-BA early treatment group and the late treatment group were significantly reduced, m-P14-BA early treatment group vs. disease control group: 6.153±0.624 vs. 7.772±1.01mmol / L, P=0.0075; late treatment group vs. disease control group: 6.215±0.620 vs. 7.772±1.01mmol / L, P=0.0092, see Figure 2 C.

[0127] In summary, the clinical indicators of renal injury in rats in each group treated with m-P14-BA were significantly decreased, and m-P14-BA treatment can significantly improve experimental anti-GBM rat nephritis.

[0128] 3.2m-P14-BA treatment inhibits intramolecular epitope expansion induced by α3-P14

[0129] In this study, the ELISA method was used to detect the circulating antibody levels and antigenic epitopes of rats after treatment with m-P14-BA. At week 6, autoantibodies against the immunogen α3127-148 peptide segment were produced in the circulation of rats in both the disease control group and the treatment group. Compared with the disease control group, the autoantibodies in the early and late treatment groups of m-P14-BA were significantly reduced (1.277±0.269 vs.1.63±0.118, P=0.015; 1.182±0.371 vs.1.63±0.118, P=0.018), see Figure 2 D.

[0130] Epitope expansion was observed in all rats in the disease control group after immunization, i.e., antibodies against the complete protein α3(IV)NC1 appeared in the circulation. Compared with the disease control group, at week 6, the level of antibodies against the complete α3(IV)NC1 protein in the circulation of rats in the m-P14-BA early treatment group was significantly reduced (0.138±0.14 vs. 0.44±0.158, P=0.0057); the level of antibodies against the complete α3(IV)NC1 protein in the circulation of rats in the m-P14-BA late treatment group was not significantly reduced (0.235±0.186 vs. 0.44±0.158, P=0.0669), see Figure 2 E. Early treatment with m-P14-BA can hinder the expansion of intramolecular antigen epitopes caused by the immunogen α3127-148 peptide segment.

[0131] 3.3m-P14-BA treatment alleviates renal pathological damage in the rat anti-GBM disease model

[0132] After 6 weeks of treatment, the rats were killed and the renal cortex was obtained for staining to observe renal pathological damage. Compared with the healthy control rats, the rats in the disease control group showed typical crescentic nephritis. Figure 3 AD, immunofluorescence examination of frozen sections of kidneys showed IgG deposition along the GBM line ( Figure 3 EH). The renal pathological damage of rats in each group treated with m-P14-BA was reduced to varying degrees.

[0133] Compared with the disease control group, only a small number of crescents were formed in the kidneys of rats in the early treatment group of m-P14-BA, and the proportion of crescents in the late treatment group was also significantly reduced (early treatment group vs. disease control group: 12.17±5.90 vs. 61.5.0±21.38%, P=0.0003; late treatment group vs. disease control group: 20.83±13.91 vs. 61.5.0±21.38%, P=0.0029), see Figure 3 I; The IgG immunofluorescence staining of the frozen sections of the kidneys in the early treatment group of m-P14-BA was significantly weakened (early treatment group vs. disease control group: 0.47±0.4 vs. 1.8±0.29, P<0.0001), and the glomerular IgG deposition of rats in the late treatment group of m-P14-BA was also weakened to a certain extent (1.2±0.30 vs. 1.8±0.29, P=0.0065), see Figure 3 J.

[0134] In summary, m-P14-BA treatment can be observed to significantly reduce urine protein, blood urea nitrogen levels, reduce circulating antibody production, and significantly reduce the proportion of renal pathological glomerular crescents and IgG deposition. The above results show that m-P14-BA intervention can significantly reduce experimental anti-GBM glomerulonephritis in the early treatment group and the late treatment group.

[0135] Comparison of the therapeutic effects of peptide drugs obtained by short-chain fatty acid-coupled peptides (m-P14) against glomerular basement membrane disease

[0136] We used the modified polypeptide and control therapeutic peptide m-P14 to treat the anti-GBM nephritis rat animal model. The specific experimental methods and detection methods were the same as those described in the above examples.

[0137] The results showed that stearic acid-coupled peptide (mP14-SA), albumin-coupled peptide (mP14-ALB), interchain disulfide bond-modified peptide (mP14-SS), intrachain disulfide bond-modified peptide (intrachain SS), m-P14 peptide antibody (mP14-Ab) and truncated peptide (short) had no significant therapeutic effect ( Figure 4 However, the peptides (m-P14-2A and m-P14-BA) coupled with butyric acid (2-aminobutyric acid (2A) and butyric acid (BA)) have significant therapeutic effects ( Figure 5 ), and after stopping the drug administration, the proportion of rats in the butyrate-coupled polypeptide treatment group that reappeared the disease was lower than that in the m-P14 treatment group, indicating that its effect was better than that of m-P14, that is, the modification was successful. We then used butyrate-coupled polypeptides to treat the rat anti-GBM disease model in the late stage, that is, after the onset of the disease, butyrate-coupled polypeptides showed a good therapeutic effect ( Figure 6 ).

[0138] The above results show that stearic acid modified polypeptide (m-P14-stearic acid), albumin modified polypeptide (m-P14-albumin), disulfide bond modified polypeptide (interchain SS, intrachain SS) have no therapeutic effect on the GBM nephritis rat model, while butyric acid modified polypeptide (m-P14-2A, m-P14-BA) has a significant therapeutic effect. It can be seen that although stearic acid modification, albumin modification, and disulfide bond modification are all common modification strategies for extending the half-life of small molecule polypeptides known in the art, they are used to modify the small molecule polypeptide m-P14 with a clear therapeutic effect against GBM disease. On the contrary, there is no therapeutic effect. That is, before experimental verification, the technicians in this field could not predict whether the butyric acid modified polypeptide (m-P14-2A (2-aminobutyric acid), m-P14-BA (butyric acid)) has a therapeutic effect against GBM disease, that is, the butyric acid-coupled polypeptide claimed for protection in this application has achieved unexpected technical effects.

[0139] The above results indicate that butyrate-coupled peptides have good therapeutic effects, and their effect in delaying the onset of the disease is stronger than that of m-P14. We further studied their therapeutic mechanism, and the results showed that m-P14-BA and m-P14-2A can significantly inhibit the production of autoantibodies, and their effects are stronger than those of m-P14 ( Figure 7 ).

[0140] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. A coupled polypeptide based on butyric acid coupling, characterized in that: The coupling polypeptide is obtained by modifying the polypeptide sequence with butyric acid or 2-aminobutyric acid; The coupled polypeptide obtained by modifying the polypeptide sequence with butyric acid is: C4H8O2-(K)n-linker-TDIPPCPHGWSSLWKGFSFIMF; The coupled polypeptide obtained by modifying the polypeptide sequence with 2-aminobutyric acid is: C4H9NO2-(K)n-linker-TDIPPCPHGWSSLWKGFSFIMF.

2. The coupled polypeptide according to claim 1, characterized in that The linker includes 6-aminohexanoic acid and / or β-alanine.

3. The coupled polypeptide according to claim 2, characterized in that The linker is 6-aminohexanoic acid.

4. The coupled polypeptide according to claim 1, characterized in that The n is selected from any integer value between 3-8.

5. The coupled polypeptide according to claim 4, characterized in that Said n=5.

6. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the coupled polypeptide according to any one of claims 1 to 5.

7. A pharmaceutical preparation, characterized in that The pharmaceutical preparation comprises the coupled polypeptide according to any one of claims 1 to 5.

8. The pharmaceutical preparation according to claim 7, characterized in that The pharmaceutical preparation comprises a pharmaceutically acceptable carrier and / or excipient; Optionally, the dosage form of the pharmaceutical preparation includes injection, lyophilized powder injection, microspheres, powder, powder spray, capsule, tablet, pill, nasal spray, aerosol, enteric coating, microemulsion or composite emulsion.

9. The method for preparing the coupled polypeptide according to any one of claims 1 to 5, characterized in that: The method comprises using butyric acid or 2-aminobutyric acid to modify the polypeptide sequence TDIPPCPHGWSSLWKGFSFIMF to prepare the coupled polypeptide according to any one of claims 1 to 5.

10. Any of the following applications, characterized in that: The applications include: (1) Use of the coupled polypeptide according to any one of claims 1 to 5 in the preparation of a drug for treating and / or preventing glomerular basement membrane disease; (2) Use of the coupled polypeptide according to any one of claims 1 to 5 in the preparation of a pharmaceutical composition for treating and / or preventing glomerular basement membrane disease; (3) Use of the coupled polypeptide according to any one of claims 1 to 5 in the preparation of a pharmaceutical preparation for treating and / or preventing anti-glomerular basement membrane disease.

Citation Information

Patent Citations

  • Polypeptide and use thereof in anti-glomerular basement membrane disease

    CN111825760A

  • Polypeptide compound specifically targeting sort1, and drug conjugate thereof

    WO2023165476A1